The Library
Treatment & Research reports
122 reports, newest first · page 3 of 5
2026
- TGF-β Cut Mesothelioma Growth up to 70% in Lab Models
- Connecticut Mesothelioma by the Numbers
- Oregon Mesothelioma by the Numbers
- Mesothelioma Survival Rates by Treatment Type
- 8 Mesothelioma Trials Compared: Results Side by Side Data
- Pelvic Mesothelioma Shrinks 83% With Immunotherapy
- Durvalumab Plus Chemo Doubles Meso Survival
- UK Trials Proton Beam Therapy for Mesothelioma
- Hawaii Identifies L-BAM, Treatable Mesothelioma
- Mesothelioma Rates by State: California Leads (2026)
- Mesothelioma Risk by Occupation: 2026 Data
- Veterans and Mesothelioma: Risk by Military Branch
- CheckMate-743 at Five Years: 14% Still Alive
- DREAM3R: Durvalumab Plus Chemo Falls Short
- Baylor-Duke NEMO Trial Tests Immuno Before Surgery
- Blood Test Predicts Immunotherapy Response in Meso
- Mount Sinai P/D Surgery: Zero Mortality in Study
- UCSF Proposes First Peritoneal Meso Staging System
- A Mesothelioma Drug That Starves Tumors Just Passed Its Phase 3 Trial
- Ikena Halts Mesothelioma Drug IK-930 After 53% Cuts
- UV1 Vaccine Gets FDA Fast Track for Mesothelioma
- A2 Bio BASECAMP-1 Screening Study (NCT04981119)
- A2 Bio EVEREST-2 CAR-T Phase 1/2 Trial (NCT06051695)
- UTC CAR-T Phase 1 Trial (NCT06256055)
- NCI TNhYP218 CAR-T Phase 1 Trial (NCT06885697)
- CAR-T Trial: Phase 1 Study for Pleural Mesothelioma
- Immunotherapy Trial: Phase 1 Study for Mesothelioma
- NCI HIPEC Phase 1 Trial (NCT04847063)
- NCI HIPEC Phase 2 Trial (NCT05001880)
- MSK HIPEC Phase 2 Trial (NCT06057935)